Peter Ciszewski, CheckRare
Rare Disease Discussions
News and clinical perspective including CME programs focused on rare diseases. CheckRare focuses on rare and neglected diseases.
Be sure to visit the podcast's website and support the creator: www.checkrare.com
Author
Peter Ciszewski, CheckRare
Category
Podcast website
Latest episode
Nov 19, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Priority Review for Dersimelagon in the Treatment of EPP and XLP 13.10.2026 14:51
Lukasz Jarzyna, Vice President of Rare Disease at LEO Pharma, discusses the Priority Review for dersimelagon in the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). EPP and XLP are rare congenital metabolic disorders characterized by an inborn error of porphyrin-heme biosynthesis. Signs and symptoms include painful cutaneous photosensitivity that results in tingl...
A Patient’s Journey With Essential Thrombocythemia and Polycythemia Vera 12.10.2026 16:16
Nona Baker, Co-Chair of MPN Voice and patient, discusses her journey with essential thrombocythemia (ET) and polycythemia vera (PV), including diagnosis and treatment. ET is a condition characterized by an overproduction of platelets. Abnormal blood clotting is common in these patients and may cause strokes or temporary stroke-like episodes, leg pain, swelling, pulmonary embolism, chest pain and d...
FDA CDER’s Accelerating Rare Disease Cures Program 05.10.2026 9:19
Paz Vellanki, MD, PhD, Vice President of Clinical Development at Precision for Medicine, discusses the FDA CDER’s Accelerating Rare Disease Cures (ARC) Program . The ARC Program was launched in 2022 with the goal of accelerating the development of safe and effective therapies for patients with high unmet need with rare diseases. The program has included a variety of initiatives, including several...
Zilganersen for the Treatment of Alexander Disease 05.10.2026 13:47
Amy Waldman, MD, pediatric neurologist and Medical Director of the Leukodystrophy Center at the Children’s Hospital of Philadelphia, discusses the approval of Zanvastro (zilganersen) to treat patients with Alexander disease. Alexander disease is a rare leukodystrophy that impairs neuronal signalling. Most cases of Alexander disease begin before age 2 and are described as the infantile form. Signs...
What to Expect: 2026 MGFA Scientific Session 05.10.2026 11:45
Jenny McCue, Vice President of Global Research and Clinical Development at the Myasthenia Gravis Foundation of America (MGFA) , discusses research highlights to be presented at the upcoming 2026 MGFA Scientific Session being held September 29th in Orlando, FL. Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. It mostly develops...
Topline Results From the SANRECO Trial Testing Divesiran in Polycythemia Vera 05.10.2026 10:02
Marina Kremyanskaya, MD, PhD, Associate Professor at Icahn School of Medicine at Mount Sinai, discusses the phase 2 topline findings from the SANRECO clinical trial and the evolving polycythemia vera (PV) treatment landscape. PV is a condition characterized by an increased production of red blood cells. Affected people may also have excess white blood cells and platelets. The excess cell levels le...
Results From the Voice of PBC Patient Survey 05.10.2026 7:33
Carol Roberts, President of The PBCers Organization , discusses results from the Voice of PBC patient survey. PBC is a chronic, progressive autoimmune liver disease in which the bile ducts become inflamed and damaged. This leads to the buildup of bile and causes scarring, cirrhosis, and eventual liver failure. Many people do not have symptoms when they are first diagnosed. Early symptoms may incl...
Approval of Imaavy (Nipocalimab) and its Impact on Patients With Warm Autoimmune Hemolytic Anemia 05.10.2026 7:17
Karen A. Jones, EdD, President and CEO of wAIHA Warriors , discusses the approval of Imaavy (nipocalimab) and its impact on patients with warm autoimmune hemolytic anemia (wAIHA). wAIHA is a rare hematologic autoimmune condition characterized by antibodies that attack red blood cells and lead to hemolytic anemia. Symptoms may include unusual weakness and fatigue that make daily life difficult, tac...
Spinal Muscular Atrophy: The Changing Definition of Success. An Expert Panel on the Evolution of SMA Care. 01.07.2026 53:24
Spinal muscular atrophy (SMA) has undergone a remarkable transformation over the past decade. Drs. Nancy Kuntz, Alicia Henriquez, and Angela Lek discuss how advances in disease-modifying therapies have fundamentally changed the outlook for children living with SMA, leading clinicians to rethink what constitutes a successful outcome in SMA care. Over the past decade, the management and treatment of...
Growth Hormone Deficiency: Causes, Early Detection, and Treatment (Robert Rapaport, MD) 08.06.2026 10:56
Robert Rapaport, MD, Professor of Pediatric Endocrinology, and Director of the Comprehensive Growth Center at the Icahn School of Medicine, Mount Sinai Medical Center, New York City, discusses the causes of growth hormone deficiency and its treatment. Growth failure in children is a considerable challenge for parents and pediatricians, with clinical and social stigma implications that may be avoid...
Arginine Vasopressin Deficiency (AVP-D) Overview (Christopher Romero, MD) 03.06.2026 19:14
Christopher Romero, MD, a pediatric endocrinologist at Mount Sinai Medical Center, New York City, and Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai discusses arginine vasopressin deficiency. The name of the rare disease central diabetes insipidus was changed in 2024 to better reflect its etiology. Central diabetes insipidus, a rare disease, is unrelated to the co...
Systemic Mastocytosis: Recognition, Diagnosis, and Clinical Management 18.05.2026 44:59
This accredited continuing education program is supported by an educational grant from Blueprint Medicine. It provides timely and practical education on systemic mastocytosis (SM). To obtain CME credit, visit https://checkrare.com/learning/p-systemic-mastocytosis-recognition-diagnosis-and-clinical-management/ SM is a rare, chronic disorder driven by aberrant mast cell accumulation across multiple...
Prader-Willi Syndrome: Clinical Features and Early Identification 24.04.2026 1:14:29
Merlin G. Butler, MD, Medical Geneticist and Professor, Departments of Psychiatry & Behavioral Sciences and Pediatrics, University of Kansas Medical Center, Kansas City, and one of the pioneers in Prader–Willi syndrome research, discusses the clinical features of this very rare disease and the critical importance of early identification. Prader–Willi syndrome was first reported in 1956, and d...
Submission of New Drug Application: Rusfertide for Polycythemia Vera 17.02.2026 18:35
Dinesh Patel, PhD, CEO of Protagonist Therapeutics, discusses the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV). PV is characterized by excess red blood cells in the bloodstream, increasing the risk for blood clots. Most cases of PV are acquired and occur more frequently in men than in women. The condit...
Current Issues in Gene Therapies for Lysosomal Disorders 31.12.2025 1:46:41
Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children’s Health, Delaware, USA; Alessandra d’Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children’s Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, di...
Theranostics and Lysosomal Disorders 31.12.2025 1:46:09
Duarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Portugal; Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of Medicine, Pennsylvania, USA; Betul Celik, PhD, Postdoctoral Fellow, Nemours Children’s Health, Delaware, USA; and Gregory Newby, PhD, Assistant Professor, Department of Genetic Medicine,...
Expanded Applications of AI in Lysosomal Disorders 31.12.2025 2:01:27
Oral Alpan, MD, Immunologist, Amerimmune, Virginia, USA; Svenja Keller, PhD student, University of Zurich, Switzerland; Shoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Patrick Deegan, MD, Consultant Metabolic Physician, University of Cambridge, UK; and Ravi Kamath, MD, PhD, Head of Musculoskeletal Radiol...
Organoids and Lab-Grown Models in Lysosomal Disorders 31.12.2025 1:36:02
Mia Horowitz, PhD, Tel Aviv University; Aitor Aguirre, PhD, Michigan State University, Michigan, USA; and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development. This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, an...
Nanotechnology and Lysosomal Disorders 31.12.2025 50:18
Stephan Stern, PhD, DABT, Director of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Maryland, USA; and Ruben Boado, PhD, Professor of Medicine, University of California at Los Angeles, California, USA, discuss the use of nanotechnology in the treatment of lysosomal disorders. This continuing education activity is provided th...
AI in Medicine: Transforming the Landscape of Tissue-Based Diagnostics 31.12.2025 52:29
Behzad Najafian, MD, Professor, Department of Laboratory Medicine & Pathology, Department of Medicine at the University of Washington, Washington, USA discusses the use of artificial intelligence in identifying and managing lysosomal disorders. This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), Ch...
Chapter 8: Gene Therapy Discussion and Q&A 22.12.2025 4:29
Alan Beggs, PhD Director of the Manton Center for Orphan Disease Research Sir Edwin and Lady Manton Professor of Pediatrics, Boston Children's Hospital Harvard Medical School, Boston, MA, USA Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular Disorders Professor of Clinical Pediatrics and Neurology University of Colorado School of Medicine, Children's Hospital Colorado Auro...
Chapter 7: Changes in Gene Therapy Programs to Lessons Learned from Recent Trials 22.12.2025 5:18
Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular Disorders Professor of Clinical Pediatrics and Neurology University of Colorado School of Medicine, Children's Hospital Colorado Aurora, CO, USA How have programs adapted to the experiences from clinical trials? I'm just looking at SMA because we've had SMA. We've had onasemnogene around for the longest period of time. We wa...
Chapter 6: Understanding and Preparing Risk Factors Associated With AAV Gene Therapies 22.12.2025 6:45
Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular Disorders Professor of Clinical Pediatrics and Neurology University of Colorado School of Medicine, Children's Hospital Colorado Aurora, CO, USA Now, with our collective experience, we can at least put together the information that we have in terms of what can we expect and what's the timeline that we expect in terms of our p...
Chapter 5: Factors Impacting Safety and Efficacy of AAV Mediated Gene Therapies 22.12.2025 5:54
Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular Disorders Professor of Clinical Pediatrics and Neurology University of Colorado School of Medicine, Children's Hospital Colorado Aurora, CO, USA The gene transfer trials for musculoskeletal disorders, if we look at musculoskeletal and neurologic disorders, we really do have the highest success rate in terms of treatment, but...
Ch 4: Clinical Safety and Efficacy Observed in AAV Mediated Gene Therapy Programs in DMD, SMA, XLMTM 22.12.2025 4:51
Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular Disorders Professor of Clinical Pediatrics and Neurology University of Colorado School of Medicine, Children's Hospital Colorado Aurora, CO, USA As we talk about the gene transfer therapies and the modalities that we have to use, it's really interesting. Yesterday, with our keynote speaker, you could see this logarithmic gro...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.